Protalix BioTherapeutics, Inc. Dilutive Securities, Effect on Basic Earnings Per Share
Protalix BioTherapeutics, Inc. (PLX) reported Dilutive Securities, Effect on Basic Earnings Per Share of $39.00 thousand for the 12-month period ending 2024-12-31, per its 10-K filed 2026-03-18.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:DilutiveSecurities · last filed 2026-03-18
- Protalix BioTherapeutics, Inc. dilutive securities, effect on basic earnings per share for the quarter ending 2024-09-30 was -$503.00K.
- Protalix BioTherapeutics, Inc. dilutive securities, effect on basic earnings per share for the quarter ending 2023-12-31 was $442.00K.
- Protalix BioTherapeutics, Inc. dilutive securities, effect on basic earnings per share for the quarter ending 2023-09-30 was -$1.77M.
- Protalix BioTherapeutics, Inc. dilutive securities, effect on basic earnings per share for the quarter ending 2023-06-30 was -$1.75M.
- Protalix BioTherapeutics, Inc. dilutive securities, effect on basic earnings per share for fiscal 2024 was $39.00K.
- Protalix BioTherapeutics, Inc. dilutive securities, effect on basic earnings per share for fiscal 2023 was -$1.17M.
| Period end | Dilutive Securities, Effect on Basic Earnings Per Share 3 month | Dilutive Securities, Effect on Basic Earnings Per Share 6 month | Dilutive Securities, Effect on Basic Earnings Per Share 9 month | Dilutive Securities, Effect on Basic Earnings Per Share 12 month |
|---|---|---|---|---|
| 2024-12-31 | $39.00K 10-K · filed 2026-03-18 | |||
| 2024-09-30 | -$503.00K 10-Q · filed 2025-11-13 | |||
| 2023-12-31 | $442.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-18 | -$1.32M derived: sum of 2 quarters · filed 2026-03-18 | -$3.07M derived: sum of 3 quarters · filed 2026-03-18 | -$1.17M 10-K · filed 2026-03-18 |
| 2023-09-30 | -$1.77M 10-Q · filed 2024-11-14 | -$3.52M derived: sum of 2 quarters · filed 2024-11-14 | -$1.61M 10-Q · filed 2024-11-14 | |
| 2023-06-30 | -$1.75M 10-Q · filed 2023-08-07 | -$2.05M 10-Q · filed 2023-08-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |
| Protara Therapeutics, Inc. (TARA) | United States | $0.198B | -3.22 |
| Alpha Cognition Inc. (ACOG) | $0.185B | -6.77 | |
| Coherus Oncology, Inc. (CHRS) | United States | $0.182B | -1.63 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |